Download fulltext
HTML
S, J. A., Namiranian, N., Gholami, S., Elahi, M., & Rahmanian, M. (2019). Evaluation of the metformin effects on Anti-Müllerian Hormone in women with polycystic ovarian syndrome: A double-blind randomized clinical trial. International Journal of Reproductive BioMedicine (IJRM), 17(2), 143–144. https://doi.org/10.18502/ijrm.v17i2.3992
https://doi.org/10.18502/ijrm.v17i2.3992
statistics
- 338 Abstract Views
- 123 PDF Views
- 0 HTML Views
- Cited by 1 article
authors
-
Jam Ashkezari S
No author data available.
-
Nasim Namiranian
No author data available.
-
Somaye Gholami
No author data available.
-
Maryam Elahi
No author data available.
-
Masoud Rahmanian
No author data available.
Published Date
- Mar 20, 2019
Evaluation of the metformin effects on Anti-Müllerian Hormone in women with polycystic ovarian syndrome: A double-blind randomized clinical trial
Abstract
This is a Letter to the Editor and does not have an abstract.
References
[1] De Leo V, La Marca A, Ditto A, Morgante G, Cianci A. Effects of metformin on gonadotropin-induced ovulation in women with polycystic ovary syndrome. Fertil Steril 1999; 72: 282–285.
[2] Laven JS, Mulders AG, Visser JA, Themmen AP, De Jong FH, Fauser BC. Anti-Mullerian hormone serum concentrations in normoovulatory and anovulatory women of reproductive age. J Clin Endocrinol Metab
2004; 89: 318–323.
[3] Dewailly D, Pigny P, Soudan B, Catteau-Jonard S, Decanter C, Poncelet E, et al. Reconciling the definitions of polycystic ovary syndrome: the ovarian follicle number and serum anti-Mullerian hormone concentrations aggregate with the markers of hyperandrogenism. J Clin Endocrinol Metab 2010; 95:4399–4405.
[4] Romualdi D, De Cicco S, Tagliaferri V, Proto C, Lanzone A, Guido M. The metabolic status modulates the effect of metformin on the antimullerian hormone-androgens-insulin interplay in obese women with polycystic ovary syndrome. J Clin Endocrinol Metab 2011; 96: E821–E824.
[5] Di Pietro M, Parborell F, Irusta G, Pascuali N, Bas D, Bianchi MS, et al. Metformin regulates ovarian angiogenesis and follicular development in a female polycystic ovary syndrome rat model. Endocrinology 2015; 156: 1453–1463.
[2] Laven JS, Mulders AG, Visser JA, Themmen AP, De Jong FH, Fauser BC. Anti-Mullerian hormone serum concentrations in normoovulatory and anovulatory women of reproductive age. J Clin Endocrinol Metab
2004; 89: 318–323.
[3] Dewailly D, Pigny P, Soudan B, Catteau-Jonard S, Decanter C, Poncelet E, et al. Reconciling the definitions of polycystic ovary syndrome: the ovarian follicle number and serum anti-Mullerian hormone concentrations aggregate with the markers of hyperandrogenism. J Clin Endocrinol Metab 2010; 95:4399–4405.
[4] Romualdi D, De Cicco S, Tagliaferri V, Proto C, Lanzone A, Guido M. The metabolic status modulates the effect of metformin on the antimullerian hormone-androgens-insulin interplay in obese women with polycystic ovary syndrome. J Clin Endocrinol Metab 2011; 96: E821–E824.
[5] Di Pietro M, Parborell F, Irusta G, Pascuali N, Bas D, Bianchi MS, et al. Metformin regulates ovarian angiogenesis and follicular development in a female polycystic ovary syndrome rat model. Endocrinology 2015; 156: 1453–1463.